MedWatch

Novo Nordisk enters partnership with Belgian company

Denmark’s Novo Nordisk has entered a collaboration to discover and develop nano-antibodies with a Belgian biotech company. It is not known which disease areas the partnership will target.

Foto: Jens Lindhe

Belgium-based Ablynx says it has entered a collaboration and licensing deal with Denmark’s Novo Nordisk. The deal pertains to the discovery and development of novel multi-specific Nanobody drug candidates for use in an undisclosed disease area, with an option to expand the agreement to include a second Nanobody program.

Nanobodies are antibodies that are significantly smaller than regular antibodies, allowing them to reach the areas of the body affected by a disease more easily.

Læs hele artiklen

Få 14 dages fri adgang.

Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.

  • Adgang til alle låste artikler
  • Modtag vores daglige nyhedsbreve
  • Fuld adgang til vores app
Der skete en fejl. Prøv venligst igen senere

Få fuld adgang til dig og dine kollegaer.

Start et gratis virksomhedsprøveabonnement

Mere fra MedWatch

Relaterede

Seneste nyt

Ledige job

Se flere jobs

Se flere jobs

Latest news

Seneste nyt fra Watch Medier